Perseus Proteomics, Inc. (4882) AI Stock Analysis

• Market Cap: ¥5.06B
• Dividend Yield: N/A
• Average Volume (3M): 421.71K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.90
• Revenue Growth: 27.46%
• EPS Growth: 20.63%
• Country: JP
• Employees: 25
• Sector: Healthcare
• Sector Strength: 49
• Industry: Drug Manufacturers - General
• EPS (TTM): -11.94
• Shares Outstanding: 14,749,500
• 10 Day Avg. Volume: 791,770
• 30 Day Avg. Volume: 421,706
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 42 Neutral
• Price Target: ―

Perseus Proteomics, Inc. faces significant financial challenges marked by negative profitability and cash flow issues despite strong revenue growth. The technical indicators suggest downward momentum and possible oversold conditions, further weighing on the stock. Valuation is difficult due to negative earnings, resulting in a low overall stock score.

Perseus Proteomics, Inc. Business Overview & Revenue Model

Company Description

Perseus Proteomics, Inc. (4882) is a biotechnology company focused on the research and development of antibody-based therapeutics. The company operates in the life sciences sector, specializing in the discovery and commercialization of monoclonal antibodies for the treatment of various diseases. Its core products include therapeutic antibodies that target specific proteins involved in disease processes.

How the Company Makes Money

Perseus Proteomics, Inc. generates revenue primarily through the development and commercialization of antibody-based therapeutics. The company's revenue streams include licensing agreements, collaborations with pharmaceutical and biotechnology companies, and sales of its developed products. Significant partnerships with larger pharmaceutical firms may provide upfront payments, milestone payments upon reaching certain development stages, and royalties from product sales. The company also invests in proprietary research to build a robust pipeline of potential therapies that can be licensed or sold, further contributing to its earnings.

Perseus Proteomics, Inc. Financial Statement Overview

Summary

Perseus Proteomics, Inc. shows strong revenue growth but struggles with profitability due to high operational losses. The balance sheet is robust with no debt, providing stability; however, ongoing cash flow challenges and operational inefficiencies are concerning despite a healthy cash reserve.

Income Statement

The company has shown a consistent increase in revenue over the years, with a TTM revenue of 111.4 million JPY. However, persistent negative EBIT and EBITDA margins indicate high operational costs and inefficiencies. Despite having a high gross profit margin of 85.4%, the net profit margin remains negative due to substantial losses. This significantly impacts the overall profitability and financial health of the company.

Balance Sheet

The balance sheet shows a strong equity base with zero debt, resulting in a favorable debt-to-equity ratio of 0. The equity ratio is robust at 82.1%, indicating financial stability. Nevertheless, the company’s persistent net losses are concerning, as they negatively affect the return on equity, which is deeply in the negative territory.

Cash Flow

The cash flow statement highlights a negative free cash flow, which has shown some improvement in the TTM. The operating cash flow is consistently negative, which raises concerns about the company's ability to sustain operations without external financing. Despite this, the company has a strong cash position, helping it to manage its operational needs.

Breakdown	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	120.38M	100.40M	94.20M	71.93M	67.95M
Gross Profit	104.05M	87.69M	86.53M	67.75M	64.10M
EBITDA	-899.49M	-892.00M	-692.00M	-471.00M	-411.23M
Net Income	-904.80M	-1.10B	-787.00M	-599.02M	-413.22M
Balance Sheet
Total Assets	1.82B	1.69B	2.57B	3.30B	1.12B
Cash, Cash Equivalents and Short-Term Investments	1.67B	1.54B	2.44B	3.21B	1.07B
Total Debt	0.00	0.00	0.00	0.00	0.00
Total Liabilities	386.43M	295.46M	170.10M	148.38M	34.91M
Stockholders Equity	1.43B	1.40B	2.40B	3.15B	1.08B
Cash Flow
Free Cash Flow	-794.64M	-992.87M	-734.82M	-510.71M	-425.66M
Operating Cash Flow	-719.49M	-833.90M	-564.27M	-476.84M	-422.84M
Investing Cash Flow	-75.16M	-150.34M	-212.99M	-33.87M	-2.82M
Financing Cash Flow	923.38M	63.94M	-20.00K	2.65B	1.01B

Perseus Proteomics, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 343.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4882, the sentiment is Negative. The current price of 343 is below the 20-day moving average (MA) of 381.70, below the 50-day MA of 398.60, and below the 200-day MA of 535.59, indicating a bearish trend. The MACD of -19.01 indicates Positive momentum. The RSI at 29.99 is Positive, neither overbought nor oversold. The STOCH value of 9.47 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4882.

Perseus Proteomics, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4884	54 Neutral	¥3.32B	―		―	-8.56%	-7.26%
Sector *	51 Neutral	$7.83B	-0.15	-40.10%	2.29%	21.46%	-2.01%
4588	44 Neutral	¥16.77B	―		―	-9.04%	2.12%
4892	44 Neutral	¥5.86B	―		―	8.12%	-19.12%
4882	42 Neutral	¥5.06B	―		―	27.46%	20.63%
4883	39 Underperform	¥6.77B	―		―	―	64.87%
4881	38 Underperform	¥4.66B	―		―	965.85%	-42.78%

Perseus Proteomics, Inc. Corporate Events

Perseus Proteomics Releases FY2025 Business Forecasts Amid Licensing Challenges

Perseus Proteomics Inc. announced its business forecasts for the fiscal year ending March 31, 2025, with a focus on licensing agreements for its pipeline projects PPMX-T002 and PPMX-T003. The company anticipates significant R&D and administrative expenses, impacting its financial results. Despite challenges in forecasting due to incomplete licensing activities, Perseus Proteomics remains committed to maximizing the value of its projects, which could influence its market positioning and stakeholder interests.

Perseus Proteomics Completes Phase I Trial Report for PPMX-T003

Perseus Proteomics Inc. announced the completion of a clinical study report for its Phase I trial of PPMX-T003, an anti-transferrin receptor 1 antibody, in patients with polycythemia vera. The trial, which involved six subjects, demonstrated safety and indicated efficacy, with five subjects experiencing a 12-week period without the need for phlebotomy. The results have no impact on the company’s fiscal year 2025/3 business results.

Perseus Proteomics Updates PPMX-T003 Project Details

Perseus Proteomics Inc. has announced an amendment regarding its PPMX-T003 project, which is part of a drug discovery support program for orphan drugs. The amendment clarifies that the research group led by Dr. Ai Kotani at Osaka University, rather than Osaka Metropolitan University, has identified PPMX-T003 as a potential therapeutic drug for ANKL. This correction may impact stakeholders’ understanding of the project’s progress and the company’s collaboration with academic institutions.

Perseus Proteomics’ PPMX-T003 Gains Support for Orphan Drug Development

Perseus Proteomics Inc. announced that its drug candidate, PPMX-T003, intended for treating aggressive NK cell leukemia, has been selected for the Drug Discovery Support Program for Orphan drugs by Japan’s AMED. This selection supports the ongoing clinical trials, which have been extended by a year, and provides a subsidy of 100 million yen to aid in trial expenses, potentially impacting the company’s financial forecast for FY2026/3.

Perseus Proteomics Reports Financial Adjustments and Losses

Perseus Proteomics Inc. reported non-operating income, expenses, and extraordinary losses in the first nine months of the fiscal year ending March 2025. The company experienced gains from foreign exchange, outsourcing services, and interest, but also incurred costs related to capital increase and share issuance. A significant impairment loss on non-current assets was recorded, impacting the financial results for the third quarter, as announced.

Perseus Proteomics Reports Increased Sales but Continued Losses

Perseus Proteomics Inc. reported its financial results for the nine months ending December 31, 2024, showing a small increase in net sales by 15.9% compared to the previous year. Despite this, the company continues to experience financial losses, with a net loss recorded. The financial position showed an increase in total assets and net assets, but the company refrained from providing a forecast for the fiscal year ending March 31, 2025, citing difficulties in making rational predictions.